Particularly, inhibition of PRMT5 reduces the tumor growth via Myc pathway and inhibits epithelial-mesenchymal transition through EGFR-β-catenin axis in pancreatic cancer [19, 20]. The gene discussed is MYC; the disease is familial pancreatic carcinoma.